Physician profile
Adib Kassas
NPI 1386694156
$1,444.09
in general payments reported to CMS, 2019-2025
20 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $38.41 · 2021: $133 · 2022: $343 · 2023: $206 · 2024: $244 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.77 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $203.91 | 2022-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $138.42 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $118.27 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $96.97 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $72.78 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.55 | 2021-2025 | Caplyta |
| Acadia Pharmaceuticals INC | $67.31 | 2022-2025 | Nuplazid |
| Axsome Therapeutics, INC. | $61.01 | 2023-2025 | Sunosi |
| Livanova USA, INC. | $55.05 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Indivior INC. | $53.66 | 2022-2024 | Perseris |
| Allergan, INC. | $50.26 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.13 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $39.33 | 2022-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $32.39 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $28.99 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $20.70 | 2023 | Jornay Pm |
| Corium, LLC | $17.42 | 2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $15.63 | 2019 | |
| Harmony Biosciences LLC | $8.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adib Kassas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.